Elysium Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Elysium Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $70.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Elysium Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $70.1M Trade | TransData Nexus

Elysium Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $70.1M Total Trade · DGFT Verified

Elysium Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $70.1M across 9 products in 5 therapeutic categories. Based on 1,460 verified export shipments from Indian Customs (DGFT) records, Elysium Pharmaceuticals Limited is the #1 Indian exporter in 1 product including Diphenhydramine. Top exports include Amino ($24.8M), Acetaminophen ($24.7M), Diphenhydramine ($7.7M).

Elysium Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Elysium Pharmaceuticals Limited pharmaceutical export portfolio — 9 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Elysium Pharmaceuticals Limited? — Company Overview & Market Position

Elysium Pharmaceuticals Limited, established in 1996, is a prominent Indian pharmaceutical exporter specializing in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Vadodara, Gujarat, India, with its registered office located at Plot No. 1175, P.O. Dabhasa, Tal. Padra, Vadodara, Gujarat 391440. Incorporated as a public limited company, Elysium Pharmaceuticals holds the Corporate Identification Number (CIN) U24231GJ1995PLC024164. The company has demonstrated significant financial growth, with a 93.92% increase in total revenue for the fiscal year ending March 31, 2023, compared to the previous year. As of March 3, 2025, Elysium Pharmaceuticals employed 337 professionals, reflecting its expanding operations and commitment to quality manufacturing. The company's official website is www.elysiumpharma.com.

What Does Elysium Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amino$24.8M 2Acetaminophen

Product Portfolio — Top 9 by Export Value

Elysium Pharmaceuticals Limited exports 9 pharmaceutical products across 5 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amino	Nutritional Supplements	$24.8M	496	6.1%	2
2	Acetaminophen	Analgesics & Antipyretics	$24.7M	494	8.4%	2
3	Diphenhydramine	Antihistamines & Allergy	$7.7M	174	19.0%	1
4	Guaifenesin	Respiratory & OTC	$4.4M	91	14.4%	2
5	Phenylephrine	Respiratory & OTC	$3.8M	75	4.4%	3
6	Aspirin	Analgesics & Antipyretics	$1.6M	37	4.1%	7
7	Caffeine	Respiratory & OTC	$1.5M	50	1.4%	10
8	Dextromethorphan	Respiratory & OTC	$1.4M	29	7.4%	3
9	Docusate	Gastrointestinal	$292.3K	14	2.7%	5

Elysium Pharmaceuticals Limited exports 9 pharmaceutical products across 5 therapeutic categories with a total export value of $70.1M. The company is the #1 Indian exporter in 1 product: Diphenhydramine. The top category is Analgesics & Antipyretics (37.5% of portfolio), followed by Nutritional Supplements (35.4%), indicating a concentrated portfolio with the top 5 products accounting for 93.2% of total export value.

Elysium Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Elysium Pharmaceuticals operates a state-of-the-art manufacturing facility located in Dabhasa, Gujarat, India. The plant is equipped with modern, high-speed machinery that adheres to current Good Manufacturing Practices (cGMP) and WHO-GMP standards. The facility specializes in the production of both sterile (liquid and dry parenteral) and non-sterile (tablets, capsules, and liquid orals) formulations. Notably, the plant has the capacity to produce 100,000 bottles of liquid orals per day, demonstrating its substantial production capabilities.

3Key Leadership

Elysium Pharmaceuticals is led by a team of experienced professionals committed to the company's growth and adherence to quality standards. The leadership includes:

Yashwantrai Chunibhai Patel: Managing Director, serving since September 25, 2015.

Shitalkumar Navnitbhai Patel: Whole-Time Director, appointed on January 30, 2020.

Vithalbhai Shankerbhai Patel: Director.

Jinkal Darshan Patel: Whole-Time Director.

Chandani Ankitkumar Jhanwar: Director, appointed on February 17, 2023.

This leadership team is dedicated to steering Elysium Pharmaceuticals towards continued success and compliance with international standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Elysium Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Elysium Pharmaceuticals has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds approvals from the US Food and Drug Administration (FDA) and Health Canada, indicating compliance with stringent regulatory standards. Elysium's manufacturing facility is cGMP 21 and WHO-GMP compliant, reflecting adherence to international manufacturing practices. The company's products are available in over 30 international markets, demonstrating its global reach and acceptance.

2Emerging Markets

Elysium Pharmaceuticals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GMP standards facilitates access to these regions, as WHO prequalification is often a prerequisite for market entry. By meeting international quality standards, Elysium ensures its products are accessible to a broader patient population in these developing markets.

3Geographic Strategy

Elysium Pharmaceuticals demonstrates a diversified geographic strategy, with a presence in both regulated and emerging markets. This approach mitigates concentration risk and positions the company to capitalize on growth opportunities worldwide. The strategic direction focuses on expanding market reach while maintaining compliance with international regulatory standards, ensuring sustainable growth and global competitiveness.

Elysium Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Elysium Pharmaceuticals' manufacturing facility is registered with the US FDA, indicating compliance with US regulatory requirements. The company has approved Abbreviated New Drug Applications (ANDAs) for its products, allowing for the marketing of generic drugs in the United States. Additionally, Elysium has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its drug substances. The facility has undergone FDA inspections, which have been satisfactory, further affirming its adherence to US manufacturing standards.

2WHO & EU GMP

Elysium Pharmaceuticals' manufacturing facility holds WHO-GMP certification, demonstrating compliance with the World Health Organization's Good Manufacturing Practices. This certification is crucial for accessing international markets, particularly in developing regions. The facility also adheres to EU GMP standards, ensuring that its products meet the quality requirements for distribution within the European Union. These certifications underscore Elysium's commitment to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

Elysium Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Elysium Pharmaceuticals operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly available, Elysium's adherence to international quality standards, such as WHO-GMP and EU GMP certifications, positions it favorably in the market. The company's diverse product portfolio and established presence in over 30 international markets further enhance its competitive standing. Elysium's focus on quality manufacturing and regulatory compliance differentiates it from competitors, contributing to its reputation as a preferred contract manufacturer.

2Key Differentiators

Elysium Pharmaceuticals' key differentiators include its adherence to stringent manufacturing standards, such as cGMP 21 and WHO-GMP certifications, and its capacity to produce a wide range of pharmaceutical formulations. The company's manufacturing facility's ability to produce 100,000 bottles of liquid orals per day demonstrates its substantial production capabilities. Elysium's established relationships with leading multinational companies and its presence in over 30 international markets underscore its reliability and global reach.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Elysium Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Elysium Pharmaceuticals has a strong track record in pharmaceutical manufacturing, with a significant export volume of $70.1 million USD across 1,460 shipments. The company's portfolio includes nine products across five therapeutic categories, with the top five products accounting for 93.2% of the total export value. Elysium's adherence to international quality standards, such as WHO-GMP and EU GMP certifications, and its capacity to produce 100,000 bottles of liquid orals per day, reflect its reliability and consistency in meeting market demands.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the manufacturing facility is registered with the US FDA and that the products have approved ANDAs. Verification can be done through the FDA's official website or by contacting the FDA directly.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Elysium Pharmaceuticals Limited

How many pharmaceutical products does Elysium Pharmaceuticals Limited export from India?

Elysium Pharmaceuticals Limited exports 9 pharmaceutical products across 5 therapeutic categories. The top exports are Amino ($24.8M), Acetaminophen ($24.7M), Diphenhydramine ($7.7M), Guaifenesin ($4.4M), Phenylephrine ($3.8M). Total export value is $70.1M.

What is Elysium Pharmaceuticals Limited's total pharmaceutical export value?

Elysium Pharmaceuticals Limited's total pharmaceutical export value is $70.1M, based on 1,460 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Elysium Pharmaceuticals Limited the #1 Indian exporter?

Elysium Pharmaceuticals Limited is the #1 Indian exporter in 1 products: Diphenhydramine (19.0% market share).

What therapeutic categories does Elysium Pharmaceuticals Limited cover?

Elysium Pharmaceuticals Limited exports across 5 therapeutic categories. The largest are Analgesics & Antipyretics (37.5%, 2 products), Nutritional Supplements (35.4%, 1 products), Respiratory & OTC (15.8%, 4 products).

Get Full Elysium Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.